Utama › Mieloma Pelbagai › Oregon › Portland
Kajian klinikal Mieloma Pelbagai di Portland, OR
13 kajian untuk Mieloma Pelbagai sedang mencari peserta di lokasi dalam dan sekitar Portland (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Mengambil pesertaFasa 3
- Research Site, Portland
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Mengambil pesertaFasa 3
- Oregon Health And Science University, Portland
Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
Mengambil pesertaKajian pemerhatian
- OHSU Knight Cancer Institute, Portland
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Mengambil pesertaFasa 2
- Providence Health & Services, Portland
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Mengambil pesertaFasa 2
- Oregon Health and Science University, Portland
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Mengambil pesertaFasa 1/2
- Oregon Health and Science University /ID# 272282, Portland
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
Mengambil pesertaFasa 1
- Providence Portland Medical Center, Portland
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Mengambil pesertaFasa 3
- Research Site, Portland
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
Mengambil pesertaFasa 2
- Oregon Health & Science University, Portland
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Mengambil pesertaFasa 3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Providence Willamette Falls Medical Center, Oregon City · 12 mi jauh
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
Mengambil pesertaFasa 1/2
- Oregon Health and Science University (OHSU) Marquam Hill Campus, Portland
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
Mengambil pesertaKajian pemerhatian
- Local Institution - 0016, Portland
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- Oregon Health Sciences University, Portland
Kajian Mieloma Pelbagai di bandar lain
- New York City, NY60 kajian
- Boston, MA42 kajian
- Atlanta, GA41 kajian
- Houston, TX38 kajian
- Durham, NC37 kajian
- Nashville, TN32 kajian
- Denver, CO27 kajian
- Rochester, MN24 kajian
- St. Louis, MO24 kajian
- Columbus, OH24 kajian
- Baldwin Park, CA23 kajian
- Chicago, IL22 kajian
Kajian lain di Portland
- Kanser Paru-paru Bukan Sel Kecil46 kajian
- Kanser (semua jenis)34 kajian
- Kanser Prostat33 kajian
- Kanser Payudara33 kajian
- Kanser Metastatik29 kajian
- Kanser Kolorektal28 kajian
- Kanser Ovari27 kajian
- Kanser Paru-paru26 kajian
- Leukemia Mieloid Akut25 kajian
- Kanser Endometrium24 kajian
- Karsinoma Sel Skuamosa Kepala dan Leher19 kajian
- Kanser Pankreas19 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.